Muscle loss with GLP-1 therapy is usually part of the normal physiological response to weight loss, but personalized prevention strategies remain important for high-risk patients
GLP-1 receptor agonists can produce substantial weight loss, but concerns have emerged about whether part of this reduction reflects clinically meaningful muscle loss. At the ADA 2026 Scientific Sessions, experts debated whether lean-mass loss during GLP-1 treatment represents a normal physiological response or a potential risk, particularly in vulnerable patients. Current evidence suggests that most weight lost is fat mass and that physical function often improves, although closer monitoring may be needed in high-risk groups.
1. Most GLP-1–Related Weight Loss Comes From Fat
Evidence presented at the ADA 2026 Scientific Sessions suggests that most weight loss achieved with GLP-1 receptor agonists comes from fat mass rather than lean mass. Across trials producing at least 15% weight loss, lean mass accounted for approximately 25%–39% of the total weight lost, a range generally considered comparable with other weight-loss methods. After accounting for the fluid and protein contained in adipose tissue, the estimated lean-mass loss with semaglutide was lower than initially reported. Importantly, physical function and muscle quality often improved despite reductions in lean mass measured by DEXA.
2. High-Risk Patients May Require Closer Monitoring
Although current evidence does not show that GLP-1 therapy uniquely causes frailty or sarcopenia, excessive muscle loss may be clinically important in vulnerable populations. These include older adults, menopausal women, patients with sarcopenic obesity, recurrent weight cycling, cardiovascular disease, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, or a BMI below 30 kg/m². In these patients, substantial weight loss may worsen balance, strength, mobility, bone health, and fracture risk. Assessment should therefore include physical performance, gait speed, balance, grip strength, chair-stand ability, and other measures of function.
3. Muscle Function Matters More Than DEXA Alone
DEXA measures fat-free or lean mass, not skeletal muscle mass directly, because its measurements also include organs, water, connective tissue, and bone-related components. Methods such as MRI, CT, and particularly D3-creatine dilution may provide a more accurate assessment of skeletal muscle, although D3-creatine remains mainly available in research settings. To reduce clinically harmful muscle loss during GLP-1 treatment, clinicians should emphasize resistance exercise, adequate protein intake, and regular monitoring of strength and physical function. Overall, muscle loss with GLP-1 therapy is usually part of the normal physiological response to weight loss, but personalized prevention strategies remain important for high-risk patients.
Source
Medscape
